Biovation Featured in PRWeb

Sciessent’s MedMAP Helps Medical-Device Manufacturers Get Antimicrobial-Treated Products to Market Faster

Syndicated from PRWeb

Wakefield, Mass. (PRWEB) March 25, 2015

Sciessent, the leading provider of antimicrobial solutions, today announced that activities offered under its Medical Device Market Acceleration Program (MedMAPSM) helped Biovation obtain Class I CE Mark clearance for the new BioArmour™ Blood-Pressure Cuff Shield. Designed specifically for medical-device manufacturers, MedMAP makes the design, development and launch of antimicrobial-treated FDA 510(k) or CE Mark products as seamless and fast as possible.

Leveraging antimicrobials to reduce bacterial colonization and biofilm accumulation on surfaces has been proven to work; yet adding antimicrobial features to medical devices is still viewed as a significant modification by regulatory bodies. This extra layer of complexity has hindered many med-device manufacturers seeking regulatory approvals for these types of products. In response to this challenge, Sciessent created MedMAP to help manufacturers efficiently move antimicrobial-treated products from concept and development to regulatory approval and commercialization.

With MedMAP, Sciessent provides customers with the specialized expertise of its materials scientists, microbiologists and regulatory and marketing professionals. Acting as partners to manufacturers’ development teams, Sciessent has helped many clients successfully file and gain global approvals for medical devices featuring its branded antimicrobial technology. Most recently, Sciessent worked closely with Biovation to obtain Class I CE Mark approval for the company’s antimicrobial-treated BioArmour Blood-Pressure Cuff Shield, a disposable hygienic barrier that attaches to the blood-pressure cuff to prevent hospital-acquired infections.

“When choosing a provider of antimicrobials for our shield, we immediately turned to Sciessent – not only does it have wide-spectrum, high-kill technology, but it also acts as a partner and resource throughout the development, testing and regulatory processes,” said Kerem Durdag, CEO, Biovation. “Right now, there many ‘unknowns’ when it comes to gaining regulatory approvals for antimicrobial-treated devices, and because of that I recommend that med-device manufacturers don’t try to do it alone. Sciessent supported our risk-assessment activities necessary to obtain Class I designation vs. Class III, which significantly simplified the CE Mark approval process.”

“Antimicrobial functionality is a complex, but desired feature for today’s medical devices,” said Lise Moloney, director of business development, healthcare, Sciessent. “With MedMAP, not only is Sciessent providing antimicrobial technology, but also our partnership around design, development, testing, risk assessment and regulatory strategy.”

Sciessent has recently put together an Active Substance Master File that is on file with a Competent Authority in Europe. For med-device manufacturers looking for Class III CE Mark approval, this is a valuable resource that can be accessed and leveraged – significantly saving internal time and resources.

About Sciessent LLC
Sciessent is a leading provider of customized antimicrobial solutions that enhance the value of customers’ products. Agion antimicrobial solutions from Sciessent have been incorporated into a wide range of healthcare, industrial and consumer applications, including medical devices such as central-venous catheters and IV access ports, drinking-water applications like water filters and ice-making equipment, and textiles and apparel. The company’s brands include Agion, Agion Active and Sciessent Lava and are based on naturally occurring elements. Sciessent customers include leading international brands including Vygon, Medegen, Scotsman, Everpure, Follett, Honeywell, UnderArmour, Adidas, Reebok and Skechers.

The Agion® Antimicrobial is presently registered by the United States Environmental Protection Agency as a preservative and bacteriostatic agent for use in treated articles under 40 CFR 152.25a. The information presented herein is not intended to support or endorse public health claims for treated articles. The Agion Antimicrobial is also used in medical devices under the Food and Drug Administration in the US; those medical device claims are based on safety and efficacy testing and are limited to those approved by FDA. In the EU, the Agion Antimicrobial is used in medical devices under the Medical Device Directive: those medical device claims are based on safety and efficacy testing and are limited to those approved by the designated.

Biovation Featured in Textile World

Syndicated from Textile World

Biovation Launches Bioarmour™ Blood Pressure Cuff Shield, An Infectious Disease Barrier Product For Hospitals And Healthcare Facilities

BOOTHBAY, Maine — March 24, 2015 — Biovation has launched the BioArmour Blood Pressure Cuff Shield (BPCS) to mitigate the spread of infectious pathogens from blood pressure cuffs. This first-in-class medical product offers a multi-use barrier for prevention of hospital acquired infections (HAIs). The BPCS has been designed, tested and validated over a two-year cycle, and is now available in European, Canadian and all non-US markets. BioArmour is the first in a suite of infection and pathogen control products from Biovation.

Biovation is a technology design and manufacturing company that produces advanced, nonwoven fiber products with integrated antimicrobial properties for packaging, healthcare, specialty niche roll goods and wipes products and other specialty advanced material end products. BioArmour was developed and tested in close collaboration with a large hospital system to proactively provide solutions for the mitigation of HAIs.

The easy-to-use BioArmour BPCS is a disposable antimicrobial hygienic barrier that attaches to the blood pressure cuff to prevent direct contact of the cuff with the patient’s skin. The latex-free shield material is composed of a sustainable biopolymer impregnated with antimicrobial and antifungal agents to mitigate the propagation of a wide spectrum of pathogens in controlled release fashion. Contaminant pathogens – including MRSA, VRE, c. difficile and others – are mitigated by the blood pressure cuff shield, allowing for multi-patient use over a 24-hour period.

In lab testing, the BioArmour BPCS has been shown to kill up to 99.99-percent of tested microorganisms.  The BPCS is manufactured with green technology and a sustainable biopolymer, with an industry-leading 74-percent biocontent.  Its slim profile does not adversely impact accuracy of the blood pressure measurement data.  And, the BPCS provides another tool for risk mitigation for hospitals and healthcare facilities with proactive measures for infectious disease reduction and control.  This cost-effective system requires no staff maintenance or disinfection between patients and is targeted for in-patient, physician offices, hospice and nursing home facilities and emergency medical services.

“Our BioArmour Blood Pressure Cuff Shield is a proactive measure that helps hospitals and healthcare facilities support their infectious disease reduction and control efforts,” says Biovation Chief Executive Officer Kerem Durdag. “It is an easy-to-use and cost-effective tool that contributes to patient health and safety. The proprietary manufacturing technology we have employed sets a benchmark for our products in our pipeline.”

Sciessent partnered with Biovation to develop the antimicrobial technology. “The BioArmour Blood Pressure Cuff Shield infuses our world-class antimicrobial solutions into Biovation’s biopolymer fibers to result in a safe, non-leaching product with broad-spectrum efficacy,” says Lise Moloney, Director of Business Development – Healthcare, Sciessent. “We’re proud to have partnered with Biovation to bring this industry-leading product to market.”

The BioArmour BPCS has been registered a CE Class I medical device marked for distribution in the EU.  As a medical product, it is available for sale in Canada and all other non-US countries.  It is currently undergoing testing for US FDA approval, which is anticipated to be received in late summer 2015.

Biovation Featured in Innovation in Textiles

Syndicated from Innovation in Textiles

Biovation launches Bioarmour blood pressure cuff shield for healthcare facilities

Biovation, a technology design and manufacturing company, has launched the BioArmour Blood Pressure Cuff Shield (BPCS) to mitigate the spread of infectious pathogens from blood pressure cuffs.

blood-pressure-cuff-shield-by-biovation

This first-in-class medical product is said to offer a multi-use barrier for prevention of hospital acquired infections (HAIs). The BPCS has been designed, tested and validated over a two-year cycle, and is now available in European, Canadian and all non-US markets.

BioArmour was developed and tested in close collaboration with a large hospital system to proactively provide solutions for the mitigation of HAIs. © Biovation
The product represents the first in a suite of infection and pathogen control products from Biovation.

Antimicrobial hygienic barrier

Biovation produces advanced, nonwoven fibre products with integrated antimicrobial properties for packaging, healthcare, specialty niche roll goods and wipes products and other specialty advanced material end products. BioArmour was developed and tested in close collaboration with a large hospital system to proactively provide solutions for the mitigation of HAIs.
The easy-to-use BioArmour BPCS is a disposable antimicrobial hygienic barrier that attaches to the blood pressure cuff to prevent direct contact of the cuff with the patient’s skin.
In lab testing, the BioArmour BPCS has been shown to kill up to 99.99% of tested microorganisms.

The latex-free shield material is composed of a sustainable biopolymer impregnated with antimicrobial and antifungal agents to mitigate the propagation of a wide spectrum of pathogens in controlled release fashion. Contaminant pathogens, including MRSA, VRE, c. difficile, and others, are mitigated by the blood pressure cuff shield, allowing for multi-patient use over a 24-hour period.

Proactive measure

“Our BioArmour Blood Pressure Cuff Shield is a proactive measure that helps hospitals and healthcare facilities support their infectious disease reduction and control efforts,” commented Kerem Durdag, Biovation Chief Executive Officer. “It is an easy-to-use and cost-effective tool that contributes to patient health and safety. The proprietary manufacturing technology we have employed sets a benchmark for our products in our pipeline.”

Sciessent partnered with Biovation to develop the antimicrobial technology. “The BioArmour Blood Pressure Cuff Shield infuses our world-class antimicrobial solutions into Biovation’s biopolymer fibers to result in a safe, non-leaching product with broad-spectrum efficacy,” said Lise Moloney, Director of Business Development – Healthcare, Sciessent.
Sciessent partnered with Biovation to develop the antimicrobial technology.

The BioArmour BPCS has been registered a CE Class I medical device marked for distribution in the EU. As a medical product, it is available for sale in Canada and all other non-US countries. It is currently undergoing testing for US FDA approval, which is anticipated to be received in late summer 2015.

Sustainable biopolymer

In lab testing, the BioArmour BPCS has been shown to kill up to 99.99% of tested microorganisms. The BPCS is manufactured with green technology and a sustainable biopolymer, with an industry-leading 74% biocontent, the company reports.

Its profile does not adversely impact accuracy of the blood pressure measurement data. And, the BPCS provides another tool for risk mitigation for hospitals and healthcare facilities with proactive measures for infectious disease reduction and control.

This cost-effective system requires no staff maintenance or disinfection between patients and is targeted for in-patient, physician offices, hospice and nursing home facilities and nursing home facilities and emergency medical services.

Biovation’s Blood Pressure Cuff Shield in OR Today

Syndicated from OR Today

Biovation has launched the BioArmour Blood Pressure Cuff Shield (BPCS) to mitigate the spread of infectious pathogens from blood pressure cuffs. This first-in-class medical product offers a multi-use barrier for prevention of hospital-acquired infections (HAIs). The BPCS has been designed, tested and validated over a two-year cycle, and is available in European, Canadian and all non-U.S. markets. BioArmour is the first in a suite of infection and pathogen control products from Biovation.

Biovation is a technology design and manufacturing company that produces advanced, non-woven fiber products with integrated antimicrobial properties for packaging, health care, specialty niche roll goods and wipes products and other specialty advanced material end products. BioArmour was developed and tested in close collaboration with a large hospital system to proactively provide solutions for the mitigation of HAIs.

The easy-to-use BioArmour BPCS is a disposable antimicrobial hygienic barrier that attaches to the blood pressure cuff to prevent direct contact of the cuff with the patient’s skin. The latex-free shield material is composed of a sustainable biopolymer impregnated with antimicrobial and antifungal agents to mitigate the propagation of a wide spectrum of pathogens in controlled release fashion. Contaminant pathogens – including MRSA, VRE, c. difficile and others – are mitigated by the blood pressure cuff shield, allowing for multi-patient use over a 24-hour period.

In lab testing, the BioArmour BPCS has been shown to kill up to 99.99 percent of tested microorganisms. The BPCS is manufactured with green technology and a sustainable biopolymer, with an industry-leading 74 percent biocontent. Its slim profile does not adversely impact accuracy of the blood pressure measurement data.  And, the BPCS provides another tool for risk mitigation for hospitals and health care facilities with proactive measures for infectious disease reduction and control. This cost-effective system requires no staff maintenance or disinfection between patients and is targeted for in-patient, physician offices, hospice and nursing home facilities and emergency medical services.

The BioArmour BPCS has been registered a CE Class I medical device marked for distribution in the EU. As a medical product, it is available for sale in Canada and all other non-U.S. countries. It is currently undergoing testing for FDA approval, which is anticipated to be received in late summer 2015.

Biovation Launches Bioarmour™ Blood Pressure Cuff Shield

FOR RELEASE: IMMEDIATE

Biovation Launches Bioarmour™ Blood Pressure Cuff Shield, An Infectious Disease Barrier Product For Hospitals And Healthcare Facilities

Blood pressure cuff shield from Biovation offers an antimicrobial hygienic barrier against hospital acquired infections; medical product is now available to European and Canadian markets

blood-pressure-cuff-shield Biovation has launched the BioArmour Blood Pressure Cuff Shield (BPCS) to mitigate the spread of infectious pathogens from blood pressure cuffs.  This first-in-class medical product offers a multi-use barrier for prevention of hospital acquired infections (HAIs). The BPCS has been designed, tested and validated over a two-year cycle, and is now available in European, Canadian and all non-US markets. BioArmour is the first in a suite of infection and pathogen control products from Biovation.

Biovation is a technology design and manufacturing company that produces advanced, non-woven fiber products with integrated antimicrobial properties for packaging, healthcare, specialty niche roll goods and wipes products and other specialty advanced material end products. BioArmour was developed and tested in close collaboration with a large hospital system to proactively provide solutions for the mitigation of HAIs.

The easy-to-use BioArmour BPCS is a disposable antimicrobial hygienic barrier that attaches to the blood pressure cuff to prevent direct contact of the cuff with the patient’s skin. The latex-free shield material is composed of a sustainable biopolymer impregnated with antimicrobial and antifungal agents to mitigate the propagation of a wide spectrum of pathogens in controlled release fashion. Contaminant pathogens – including MRSA, VRE, c. difficile and others – are mitigated by the blood pressure cuff shield, allowing for multi-patient use over a 24-hour period.

In lab testing, the BioArmour BPCS has been shown to kill up to 99.99% of tested microorganisms.  The BPCS is manufactured with green technology and a sustainable biopolymer, with an industry-leading 74% biocontent.  Its slim profile does not adversely impact accuracy of the blood pressure measurement data.  And, the BPCS provides another tool for risk mitigation for hospitals and healthcare facilities with proactive measures for infectious disease reduction and control.  This cost-effective system requires no staff maintenance or disinfection between patients and is targeted for in-patient, physician offices, hospice and nursing home facilities and emergency medical services.

“Our BioArmour Blood Pressure Cuff Shield is a proactive measure that helps hospitals and healthcare facilities support their infectious disease reduction and control efforts,” says Biovation Chief Executive Officer Kerem Durdag. “It is an easy-to-use and cost-effective tool that contributes to patient health and safety. The proprietary manufacturing technology we have employed sets a benchmark for our products in our pipeline.”

Sciessent partnered with Biovation to develop the antimicrobial technology. “The BioArmour Blood Pressure Cuff Shield infuses our world-class antimicrobial solutions into Biovation’s biopolymer fibers to result in a safe, non-leaching product with broad-spectrum efficacy,” says Lise Moloney, Director of Business Development – Healthcare, Sciessent. “We’re proud to have partnered with Biovation to bring this industry-leading product to market.”

The BioArmour BPCS has been registered a CE Class I medical device marked for distribution in the EU.  As a medical product, it is available for sale in Canada and all other non-US countries.  It is currently undergoing testing for US FDA approval, which is anticipated to be received in late summer 2015.

About Sciessent, LLC

Sciessent is a leading provider of customized antimicrobial solutions that enhance the value of customers’ products. Agion antimicrobial solutions from Sciessent have been incorporated into a wide range of healthcare, industrial and consumer applications, including medical devices such as central-venous catheters and IV access ports, drinking-water applications like water filters and ice-making equipment, and textiles and apparel. The company’s brands include Agion, Agion Active and Sciessent Lava and are based on naturally occurring elements. Sciessent customers include leading international brands including Vygon, Medegen, Scotsman, Everpure, Follett, Honeywell, UnderArmour, Adidas, Reebok and Skechers.

About Biovation II, LLC

Biovation is a technology design and manufacturing company that manufactures advanced non-woven fiber products with integrated antimicrobial properties for packaging, healthcare, custom advanced material OEM products, and other specialty scalable applications. Biovation has extensive experience with green and sustainable biopolymers such as polylactic acid, which comes from cornstarch. It is a portfolio company of Anania & Associates Investment Company (www.anania.biz), a Maine-based private equity fund that invests in small, well-managed businesses. For more information, call +1.207.633.0616 or visit www.biovation.com.

CONTACT: Keri Seitz: kseitz@biovation.com ; +1.207.633.0616 x 27

Biovation’s DryRight™ in Non-Woven Industry Magazine

Syndicated from Non-WovenIndustry.com

Members of the armed forces will have a new product available to them to help combat unnecessary foot injuries such as foot blisters.

Biovation, a technology design and manufacturing company that produces advanced nonwoven fiber products with integrated anti-microbial chemistries, recently produced DryRight, a tactical boot-drying product.

Funded, developed, and tested in close collaboration with the U.S. Marine Corps, DryRight was successfully tested by the warfighters at a training center in Okinawa, Japan, in addition to other users in the Middle East, Scandinavia and the Sierra Nevada mountains.

The solution works by being rolled and inserted into a wet boot when it’s not in use. The construction is comprised of PLA (polylactic acid) meltblown nonwovens, allowing the entire structure to have a super-wicking performance. Because of its absorbing and moisture locking capabilities, DryRight doesn’t need to be rung out like a towel. The insert is also composed of an antimicrobial and antifungal chemistry that allows it mitigate odor caused by pathogens, and the lining, which is a woven outer layer previously accrued by the Marine Corps, according to the company’s CEO Kerem Durdag.

The opportunity to create the product for the Marines came when Durdag got a call in 2010 as the result of a referral from a colleague.

“They were looking for a company that had some expertise in fabrics and some expertise in chemistry because they knew that the chemistry had to do certain things,” he recalls. “They called us saying that they had an issue, they had a major problem that they needed to solve, and they didn’t have an articulation on what the solution should be, but they very clearly knew what the problem was. So from their perspective, we were a company that wanted to tackle on a very tough problem. And we have been very proud to have collaborated and partnered up with them; they have done a fantastic job of testing, validating and giving us product feedback.”

Because users will be carrying DryRight around under particular conditions, the Marine Corps provided specific parameters that needed to be met by Biovation, including weight, size, usability, robustness, ruggedness and number of uses. The Marines also wanted it to have an element of sustainability, which is where the use of sustainable biopolymers came in.

“We had to do it in a way so that its weight is light and strong, and then it needs to be able to get folded up so they can stuff it in their backpack,” he says.

Durdag guarantees the product can be used up to five times under very wet conditions, but users can potentially get 10-15 uses if the boots are just dampened or moistened. Boots are completely dry after inserting the product into boots for six to eight hours.

The company spent a lot of time ensuring the structure was pliable and flexible, as warfighters would use them in various weather conditions and in fresh, brackish and salt waters.

“Whether you’re in the Arctic, in Afghanistan or in Okinawa, a lot of the tweaking and the testing we had to do was to ensure that the performance remains constant independent of weather conditions. That’s the tweaking of the chemistries; the way we make the fiber and resulting non-woven material from the PLA,” Durdag explains.

While it’s unclear whether the Dept. of Defense will purchase DryRight, Durdag says it will be available to them in June or July of this year. Biovation is also considering the production of civilian versions for hikers, fisherman, hunters and other commercial sectors.

Dryright™ Tactical Boot Dryer Sheet in MarineCorpsTimes.com

Syndicated from MarineCorpsTimes.com

While Marines are quick to joke about the medical advice they get from Navy corpsmen to change their socks, the effort can go a long way in preventing foot rot, which can drop a ground-pounder from the fight for weeks.

That’s why the Marine Corps is working with a technology and manufacturing company to develop boot inserts that mitigate odor and foot infections by drying soaked boots in hours.

The inserts already underwent testing last summer and early fall at the Corps’ Jungle Warfare Training Center in Okinawa, Japan, and could be delivered for use as early as this summer.

Biovation II, based in Maine, will begin producing the inserts on a commercial scale in June. It’s the culmination of a research and development partnership with the Marine Corps, which is searching for lightweight, quick-drying uniform items suitable for tropical climes, like the Asia-Pacific region.

Called DryRight, Marines will place the new inserts into their boots when they’re not in use for six to eight hours, according to Kerem Durdag, the company’s chief executive officer. The inserts likely would be reused five to 10 times, he said. They are technically guaranteed up to five uses, but through improvements they now have the potential to be used 10-15 times before needing replacement.

“The key goal is to keep Marines’ feet dry and eliminate odor, which is caused by pathogens,” Durdag said. “We want to mitigate them or completely deny them the opportunity to propagate. Can we cut down on the risk of fungal infections? That is where our knowledge of wound care comes in handy.”

The inserts received positive reviews during testing in Okinawa, Durdag said, although the company did change the product as a result of feedback.

“In a handful of cases, material at the seams started to lose a little mechanical strength,” he said. “Not enough for product to fail, but we want to make it stronger.”

During development, the company also made the product more flexible and pliable for easy storage, and tweaked instructions to ensure they were clear.

Most importantly, the company was able to make the inserts perform better in various types of water, whether fresh or brackish and in various temperatures, whether hot and sultry or cool.

The inserts will undergo a final field assessment, also in Okinawa, this month.

When paired with anti-microbial socks and clothing already in use by Marines, the chances for infection will be reduced, he said.

When not in use, the inserts can be easily compressed so they don’t eat up valuable space in a Marine’s pack. Marines can dry the inserts quickly by strapping them to the outside of their packs. As a result, the inserts must be durable enough to withstand the abuse they will be exposed to in combat environments.

The product is also partially constructed from “sustainable biopolymers” meaning if buried about half of it will biodegrade within 18 months. That is expected to ease the logistics burden of having to remove spent gear from the battlefield.

The testing is part of a $978,000 contract the Marine Corps awarded to Biovation II in June 2013 to develop and test super-absorbent inserts, with the goal of having a field-ready product within 20 months. The project has moved along near its original timeline.

Exactly when the Marine Corps will place its first order remains to be seen, but company will be prepared in June, Durdag said. Within another year or two, they plan to expand into the civilian market for outdoor enthusiasts, hunters and even expedition adventure travelers.

Ray Walsh Joins Biovation As Director of Operations

FOR RELEASE: IMMEDIATE

Walsh will lead Biovation’s operations groups as it prepares for ISO 13485 certification and to implement new equipment and processes

BOOTHBAY, ME – Biovation, a manufacturer of biopolymer non-woven fiber products for medical, packaging, and specialty markets, announces that Ray Walsh has joined the executive management team as Director of Operations. Walsh brings significant experience in manufacturing to his new post, where he is responsible for growing and managing the operations department, and providing leadership for Biovation’s facilities, process and manufacturing personnel.

Walsh previously served as Director – Project Manager for Biovation’s parent company, Anania & Associates. His background includes positions in diversified process industries, including pulp/paper and converting, real-time online instrumentation and process control, seafood, building products, and industrial microwave equipment manufacturing. He has served in numerous roles, including in engineering, sales, marketing, and operations. Walsh also has experience managing large crews, including a manufacturing facility and for a seafood processing/sales company .

“I am very pleased that Ray has joined our team and will lead our operations efforts as we implement our growth strategies. During the last several years we have successfully installed a unique and differentiated biopolymer non-woven manufacturing line and are now poised to leverage its continuous operation to customer specific products,” says Biovation Chief Executive Officer Kerem Durdag. ”Ray’s years of experience with and knowledge from global manufacturing companies will be beneficial to our operations in 2015 and beyond.”

Biovation will release several new products within this calendar year, including an infection control barrier product (the BioArmour™ Blood Pressure Cuff Shield), a specialty advanced product for the Department of Defense (the DryRight™), and several roll goods products for niche markets. Additionally, with the implementation of the ISO 13485 processes and systems, new manufacturing equipment is being installed to ensure high-throughput product delivery for Biovation’s growing customer base.

About Anania & Associates Investment Company LLC

Anania & Associates Investment Company LLC (AAI) is a Maine based and focused private equity firm that partners with management teams acquiring and building companies with a high potential for growth. Founded in 2008 the fund currently has 8 portfolio companies representing over 450 employees and $75 million in revenue.  AAI is a long term, regionally focused investor focused on supporting sustainable growth for its portfolio companies which include: Biovation II LLC, Elmet Technologies LLCGrow-Tech LLCLighthouse Imaging LLCMEGA Industries LLCmWAVE Industries LLCSynergistic Software Solutions LLC & TrakTec LLC.

About Biovation II, LLC

Biovation is a technology design and manufacturing company that manufactures advanced polylactic acid (PLA)-based non-woven fiber end products and roll goods with integrated antimicrobial properties for packaging, infection control, advanced wound care, hygiene, and other specialty applications. Biovation has extensive experience with green biopolymers such as,PLA, which comes from cornstarch and is completely biodegradable. For more information, call +1.207.633.0616 or visit www.biovation.com. CONTACT: Kerem Durdag: kdurdag@biovation.com; 207.632.2559